|
|
|
FDA Home Page | Search
FDA Site | A-Z Index | Contact
FDA
Dockets Entered On June 6, 2003 TABLE OF CONTENTS (Linked) | ||||||||||||
| Docket # | Title | |||||||||||
| 2000N-1571 | Enrofloxacin for Poultry: Opportunity for Hearing | |||||||||||
| 2002N-0241 | Aluminum in Large & Small Volume Parenterals | |||||||||||
| 2002N-0288 | Special Control for Eight Surgical Suture | |||||||||||
| 2003N-0193 | Ophthalmic Drug Products for Over-the-Counter Human Use; Final Monograph; Technical Amendment | |||||||||||
| 2003N-0207 | Preparation for ICH Meetings in Brussels, Belgium, July 15-18, 2003 and ICH 6 Conference in Osaka, Japan, November 12-15, 2003 | |||||||||||
| CONTENTS | ||||||||||||
| 2000N-1571 | Enrofloxacin for Poultry: Opportunity for Hearing | |||||||||||
| LET 12 | Center for Veterinary Medicine | Vol #: | 378 | |||||||||
| LET 13 | Center for Veterinary Medicine | Vol #: | 378 | |||||||||
| 2002N-0241 | Aluminum in Large & Small Volume Parenterals | |||||||||||
| NFR 1 | FDA | Vol #: | 1 | |||||||||
| 2002N-0288 | Special Control for Eight Surgical Suture | |||||||||||
| NFR 1 | FDA | Vol #: | 1 | |||||||||
| 2003E-0243 | Patent Extension for InFuse Bone Graft/LT-Cage Lumbar Tapered Fusion Device, 5,984,967 | |||||||||||
| APP 1 | SDGI Holdings, Inc. | Vol #: | 1 | |||||||||
| LET 1 | U S Patent and Trademark Office | Vol #: | 1 | |||||||||
| 2003E-0244 | Patent InFuse Bone Graft/LT-CAGE Lumbar Tapered Fusion Device, 5,782,919 | |||||||||||
| APP 1 | SDGI Holdings, Inc. | Vol #: | 1 | |||||||||
| LET 1 | U S Patent and Trademark Office | Vol #: | 1 | |||||||||
| 2003E-0245 | Patent Extension for Remodulin (Treprostinil sodium), 5,153,222 | |||||||||||
| APP 1 | Anjaneyulu Tadepalli, et al | Vol #: | 1 | ||||||
| LET 1 | U S Patent and Trademark Office | Vol #: | 1 | ||||||
| 2003E-0246 | Patent Extension for Deramaxx (deracoxib), 5,521,207, | ||||||||
| APP 1 | Pharmacia Corporation | Vol #: | 1 | ||||||
| LET 1 | U S Patent and Trademark Office | Vol #: | 1 | ||||||
| 2003E-0247 | Patent Extension for Campath (Alemtuzumab), 5,545,403 | ||||||||
| APP 1 | Millennium Pharmaceuticals Inc | Vol #: | 1 | ||||||
| LET 1 | U S Patent and Trademark Office | Vol #: | 1 | ||||||
| 2003E-0248 | Patent Extension for Extranaeal (icodextrin), 4,761,237 | ||||||||
| APP 1 | Baxter International Inc | Vol #: | 1 | ||||||
| LET 1 | U S Patent and Trademark Office | Vol #: | 1 | ||||||
| 2003E-0249 | Patent Extension for Elitek (rasburicase) 5,382,518 | ||||||||
| APP 1 | Sanofi-Synthelabo Inc | Vol #: | 1 | ||||||
| LET 1 | U S Patent and Trademark Office | Vol #: | 1 | ||||||
| 2003E-0250 | Patent Extension for Invanz (ertapenem sodium), 5,478,820 | ||||||||
| APP 1 | Merck & Co., Inc. | Vol #: | 1 | ||||||
| LET 1 | U S Patent and Trademark Office | Vol #: | 1 | ||||||
| 2003E-0251 | Patent 5,667,787, Daptacel (Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine) | ||||||||
| APP 1 | Aventis Pasteur, Inc. | Vol #: | 1 | ||||||
| LET 1 | U S Patent and Trademark Office | Vol #: | 1 | ||||||
| 2003E-0252 | Patent Extension for A180 (danofloxacin mesylate), 4,861,779 | ||||||||
| APP 1 | Pfizer, Inc. | Vol #: | 1 | ||||||
| LET 1 | U S Patent and Trademark Office | Vol #: | 1 | ||||||
| 2003E-0253 | Patent Extension for Lexapro (escitalopram oxalate), 34,712 | ||||||||
| APP 1 | Darby & Darby PC | Vol #: | 1 | ||||||
| LET 1 | U S Patent and Trademark Office | Vol #: | 1 | ||||||
| 2003N-0193 | Ophthalmic Drug Products for Over-the-Counter Human Use; Final Monograph; Technical Amendment | ||||||||
| NFR 1 | FDA | Vol #: | 1 | ||||||
| 2003N-0207 | Preparation for ICH Meetings in Brussels, Belgium, July 15-18, 2003 and ICH 6 Conference in Osaka, Japan, November 12-15, 2003 | ||||||||
| NM 1 | FDA | Vol #: | 1 | ||||||
| 2003V-0230 | Laser Light Show | ||||||||
| VAR 1 | River Palms Resort Casino | Vol #: | 1 | ||||||
Page Update November 20, 2003 jb